Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02116530 : Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
- Diagnosis of malignant disease

- No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing
regimen or anthracycline + cyclophosphamide [AC])

- Cisplatin at a dose of ?70mg/m^2, with or without other chemotherapy agent(s) OR

- Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)

- Age ?18 years

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2

- Required Initial Laboratory Values ? 120 days prior to registration

- Serum Creatinine ?2.0 mg/dL

- Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic
transaminase (SGPT) ?3 x Upper
Limit of Normal (ULN)

- Absolute neutrophil count (ANC) ?1500/mm^3

- No nausea or vomiting ? 24 hours prior to registration

- Negative pregnancy test (serum or urine) done ?7 days prior to registration, for
women of childbearing potential only (per clinician discretion)

- No severe cognitive compromise

- No known history of CNS disease (e.g. brain metastases, seizure disorder)

- No treatment with another antipsychotic agent such as risperidone, quetiapine,
clozapine, phenothiazine or butyrophenone ?30 days prior to registration or planned
during protocol therapy

- No chronic phenothiazine administration as an antipsychotic agent (patients may
receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)

- No concurrent use of amifostine

- No concurrent abdominal radiotherapy

- No concurrent use of quinolone antibiotic therapy

- No chronic alcoholism (as determined by the investigator)

- No known hypersensitivity to olanzapine

- No known cardiac arrhythmia, uncontrolled congestive heart failure or acute
myocardial infarction within the previous six months.

- No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic
agent)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02116530      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740